亲爱的研友该休息了!由于当前在线用户较少,发布求助请尽量完整地填写文献信息,科研通机器人24小时在线,伴您度过漫漫科研夜!身体可是革命的本钱,早点休息,好梦!

Abstract GS2-02: GS2-02 Trastuzumab deruxtecan versus trastuzumab emtansine in patients with HER2-positive metastatic breast cancer: Updated survival results of the randomized, phase 3 study DESTINY-Breast03

医学 内科学 曲妥珠单抗 帕妥珠单抗 转移性乳腺癌 临床终点 曲妥珠单抗 肿瘤科 紫杉烷 乳腺癌 养生 癌症 临床试验
作者
Sara Hurvitz,Roberto Hegg,Wei-Pang Chung,Seock-Ah Im,William Jacot,Vinod Ganju,Joanne Win Yang Chiu,Binghe Xu,Erika Hamilton,Srinivasan Madhusudan,Hiroji Iwata,Sevilay Altintas,Jan-Willem Henning,Giuseppe Curigliano,José Manuel Pérez-García,Anton Egorov,Yali Liu,Jillian Cathcart,Shahid Ashfaque,Javier Cortés
出处
期刊:Cancer Research [American Association for Cancer Research]
卷期号:83 (5_Supplement): GS2-02 被引量:2
标识
DOI:10.1158/1538-7445.sabcs22-gs2-02
摘要

Abstract Background: Trastuzumab deruxtecan (T-DXd) is approved in the United States and European Union for use in patients (pts) with HER2+ unresectable/metastatic breast cancer (mBC) after ≥1 prior anti–HER2 regimen(s). Approval was based on the randomized, multicenter, open-label, phase 3 DESTINY-Breast03 study (NCT03529110), in which T-DXd demonstrated statistically significant and clinically meaningful improvement in progression-free survival (PFS) compared with trastuzumab emtansine (T-DM1). At the primary interim analysis (data cutoff May 21, 2021), the risk of disease progression or death was reduced by 72% with T-DXd (P < 0.001; Cortes et al. N Engl J Med 2022). Overall survival (OS) data were immature for both treatment groups; although the prespecified cutoff for significance was not reached (NR), a trend toward benefit with T-DXd was observed. With further follow-up, we report results from the prespecified OS analysis of DESTINY-Breast03 (data cutoff July 25, 2022), including updated efficacy and safety. Methods: Pts with HER2+ mBC previously treated with trastuzumab and a taxane in either the metastatic setting or (neo)adjuvant setting with progression within 6 mo of therapy, who could have received pertuzumab, were randomly assigned 1:1 to receive T-DXd 5.4 mg/kg every 3 weeks (Q3W) or T-DM1 3.6 mg/kg Q3W until disease progression. The primary endpoint was PFS by blinded independent central review (BICR). The key secondary endpoint was OS (80% powered at 2-sided significance level of 5%); other secondary endpoints included objective response rate (ORR), duration of response (DoR), PFS based on investigator assessment, and safety. Results: 524 pts received either T-DXd (n = 261) or T-DM1 (n = 263). As of the updated data cutoff, median duration of study follow-up was 28.4 mo (range, 0.0-46.9 mo) for T-DXd and 26.5 mo (range, 0.0-45.0 mo) for T-DM1. Median treatment duration was 18.2 mo (range, 0.7-44.0 mo) for T DXd and 6.9 mo (range, 0.7-39.3 mo) for T-DM1. The risk of death was reduced by 36% (HR, 0.64; P = 0.0037) with T-DXd; median OS (mOS) was NR (95% CI, 40.5 mo-not evaluable [NE]), with 72 (27.6%) OS events, for T-DXd vs NR (95% CI, 34.0 mo-NE), with 97 (36.9%) OS events, for T-DM1. Landmark 12-mo OS rate was 94.1% (95% CI, 90.4-96.4) for T-DXd vs 86.0% (95% CI, 81.1-89.8) for T-DM1; 24-mo OS rate was 77.4% (95% CI, 71.7-82.1) for T-DXd vs 69.9% (95% CI, 63.7-75.2) for T-DM1. The P value for OS crossed the prespecified boundary (P = 0.013) and was statistically significant. mPFS by BICR was 28.8 mo (95% CI, 22.4-37.9 mo) with T-DXd, compared with 6.8 mo (95% CI, 5.6-8.2 mo) with T-DM1; HR, 0.33; nominal P < 0.000001. Key efficacy and safety results are shown in the table. Grade ≥3 treatment-emergent adverse events were experienced by 56.4% of T-DXd-treated pts and 51.7% of T DM1-treated pts. Drug-related interstitial lung disease/pneumonitis, as evaluated by an independent adjudication committee, was experienced by 39 pts (15.2%) in the T-DXd arm and 8 pts (3.1%) in the T DM1 arm; no adjudicated drug-related grade 4 or 5 events were observed in pts who received T-DXd. Conclusions: Updated results confirm the superiority of T-DXd compared with T-DM1 for pts with HER2+ mBC previously treated with an anti-HER2 therapy, with highly clinically meaningful and statistically significant benefit in OS and PFS and a manageable safety profile with longer treatment duration. Editorial Acknowledgment Under the guidance of authors, assistance in medical writing and editorial support was provided by Laura Halvorson, PhD, and Rachel Hood, PhD, of ApotheCom, and was funded by Daiichi Sankyo. Funding This study was funded by Daiichi Sankyo and AstraZeneca. Table. Summary of Efficacy Results for T-DXd and T-DM1 Citation Format: Sara Hurvitz, Roberto Hegg, Wei-Pang Chung, Seock-Ah Im, William Jacot, Vinod Ganju, Joanne Win Yang Chiu, Binghe Xu, Erika Hamilton, Srinivasan Madhusudan, Hiroji Iwata, Sevilay Altintas, Jan-Willem Henning, Giuseppe Curigliano, José Manuel Pérez-García, Anton Egorov, Yali Liu, Jillian Cathcart, Shahid Ashfaque, Javier Cortés. GS2-02 Trastuzumab deruxtecan versus trastuzumab emtansine in patients with HER2-positive metastatic breast cancer: Updated survival results of the randomized, phase 3 study DESTINY-Breast03 [abstract]. In: Proceedings of the 2022 San Antonio Breast Cancer Symposium; 2022 Dec 6-10; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2023;83(5 Suppl):Abstract nr GS2-02.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
奔跑的应助被欣喜寒烟采纳,获得10
5秒前
6秒前
whistle发布了新的文献求助10
7秒前
宁静致远完成签到,获得积分10
9秒前
foxm完成签到,获得积分10
12秒前
whistle完成签到,获得积分10
17秒前
笨笨的夏柳完成签到,获得积分10
20秒前
小马甲的应助被ZZWZHENG采纳,获得50
22秒前
文静楷瑞完成签到,获得积分10
33秒前
机灵自中完成签到,获得积分10
43秒前
酷酷海豚完成签到,获得积分10
48秒前
parantal发布了新的文献求助10
51秒前
体贴的惜文完成签到,获得积分10
1分钟前
忧虑的如雪完成签到,获得积分10
1分钟前
zhanghao完成签到,获得积分10
1分钟前
思源的应助被洁净的傲易采纳,获得10
1分钟前
1分钟前
1分钟前
flysteven92完成签到 ,获得积分10
1分钟前
1分钟前
小麻完成签到,获得积分10
1分钟前
小麻发布了新的文献求助30
1分钟前
爱听歌的香萱完成签到,获得积分10
2分钟前
周博完成签到,获得积分10
2分钟前
爆米花的应助被小麻采纳,获得10
2分钟前
NexusExplorer的应助被龙龙采纳,获得10
2分钟前
2分钟前
清新的雨文完成签到,获得积分10
2分钟前
ZZWZHENG发布了新的文献求助50
2分钟前
2分钟前
2分钟前
爱笑歌曲完成签到,获得积分10
2分钟前
FG完成签到 ,获得积分10
2分钟前
2分钟前
标致的元蝶完成签到,获得积分10
3分钟前
科研通AI6.4的应助被葛力采纳,获得10
3分钟前
神勇凡英完成签到,获得积分10
3分钟前
3分钟前
彭于晏的应助被敏感寻真采纳,获得10
3分钟前
要减肥的菀完成签到,获得积分10
3分钟前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
八旗制度の研究 600
plantTFDB 508
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8173069
求助须知:如何正确求助?哪些是违规求助? 9565519
关于积分的说明 21780407
捐赠科研通 7765088
什么是DOI,文献DOI怎么找? 3431532
关于科研通互助平台的介绍 2555638
邀请新用户注册赠送积分活动 2476668